ContraFect to Present at The Lysin Meeting
YONKERS, NY -- (Marketwired) -- 11/10/16 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces its sponsorship and participation in the 1st International Symposium on Antimicrobial Hydrolytic Enzymes, also known as "The Lysin Meeting" which is being held on November 17th and 18th at The Rockefeller University in New York City.
The Lysin Meeting is the first conference dedicated to the topic of the potential application of lysins. Lysins are enzymes derived from naturally occurring bacteriophage, viruses which infect bacteria. When produced in recombinant form and applied to bacteria, lysins cleave a key component in the structure of the bacterial peptidoglycan cell wall which results in rapid killing of the target bacteria. There will be approximately 135 attendees, including 30 speakers representing leading scientists in the field from academic, industry and regulatory arenas. ContraFect representatives will be making the following presentations:
- Keynote Speaker : Steven C. Gilman, Ph.D., Chairman and CEO, ContraFect: From Bench to Bedside: Why Patients Need New Anti-Bacterials
- Cara Cassino, M.D., EVP Research & Development and Chief Medical Officer, ContraFect: Clinical Development: Challenges and Opportunities for Targeted Lysin Therapeutics
- Raymond Schuch, Ph.D., Vice President of Research, ContraFect: The Anti-staphylococcal Post-Antibiotic Effect of Lysin CF-301
- Michael Wittekind, Ph.D., Former Chief Scientific Officer of ContraFect: Analysis of Staphylococcus aureus Resistance to Lysin CF-301
For more information regarding The Lysin Meeting, please visit the meeting website: https://thelysinmeeting.com/.
CF-301 is a recombinant bacteriophage-derived lysin with potent bactericidal activity against Staphylococcus aureus (Staph aureus), a major cause of blood stream infections, or bacteremia. CF-301 has the potential to be a first-in-class treatment for Staph aureus bacteremia. It has a novel, rapid, and specific mechanism of bactericidal action against Staph aureus and does not impact the body's natural bacterial flora. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. Combinations of CF-301 with standard of care antibiotics significantly increased bacterial killing and survival in animal models of disease when compared to treatment with antibiotics or CF-301 alone. In addition, in vitro and in vivo experiments have shown that CF-301 is highly active against biofilm infections. CF-301 was licensed from The Rockefeller University and is being developed at ContraFect and is the first lysin to enter clinical trials in the U.S.
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza.
This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, including whether CF-301 has the potential to be a first-in-class treatment for Staph aureus bloodstream infections, and ContraFect's participation in The Lysin Meeting. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contact
Source: ContraFect Corporation
Released November 10, 2016